Review of Life Science Funds and ETF’s up 15% YTD
Edited Version Published in Investor Uprising June 2011 :Updated here JY 16, 2011 Biotechnology Has Outperformed the S&P Over Five Years Medical science has always been an important area for investors and recent breakthroughs with new drugs and devices have eclipsed many of the concerns of...
Sector Watch: Energy on Fire,Techs Strong,Healthcare a Bit Weak
Large cap drug and biotech stocks sold off as buyers favor technology. Within the NASDAQ-100 up 1% led by GOOG, BIDU and SIRI. Alexion (ALXN $52.19) bucked the weakness in biotech up 1.74% but GILD, ILMN and AMGN down. Some major rotation going on today out of healthcare and into energy ( up...
Macro Rules Market: QE3 Buzz is Off
Life Science Sector Outperforms NASDAQ-100: Movers are ROSGD, VICL Biotechnology stocks sold off about 0.65% overall as industry news and fundamentals were eclipsed by MACRO issues. Concerns loom about European debt, US debt ceiling and potential default. JPMorgan earnings helped buffer losses...
Rayno Life Sciences Portfolio Update: MITI, QGEN, SGEN
Life Science Stocks are Stable in a Choppy Market; Macro Is Dominating The NASDAQ market stabilized today (but down 0.54%) after a two day sell-off that brought the qqq down to $57.79 from the $59.50 level last Thursday.The market skittishness was primarily caused by increasing concern about...
NYT Article Raises Issues with Genomics Tests with Cancer Patients
A front page article in the New York Times today by Gina Kolata, "How Bright Promise in Cancer Testing Fell Apart", chronicles a patient case study at Duke University about gene based tests for lung cancer. Additional commentary at other research institutions suggests that "good science has not...